Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL(R)/CAELYX(R)) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma - a study by the EORTC Soft Tissue and Bone Sarcoma Group

Author： Judson I.   Radford J.A.   Harris M.   Blay J.-Y.   van Hoesel Q.   le Cesne A.   van Oosterom A.T.   Clemons M.J.   Kamby C.   Hermans C.   Whittaker J.   Donato di Paola E.   Verweij J.   Nielsen S.  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.37, Iss.7, 2001-05, pp. : 870-877

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue sarcomas. The experience of the EORTC soft tissue and bone sarcoma group

By Nielsen Ole S.   Mouridsen Henning   Daugaard Soren   Verweij Jaap   Dombernowsky Per   Van Glabbeke Martine   Kirkpatrick Anne  

Sarcoma, Vol. 4, Iss. 1-2, 2000-03 ,pp. : 31-35

Informa Healthcare

Access to resources Recommend Favorite

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

By Woll P.J.   Judson I.   Lee S.M.   Rodenhuis S.   Nielsen O.S.   Buesa J.M.   Lorigan P.C.   Leyvraz S.   Hermans C.   van Glabbeke M.   Verweij J.  

European Journal of Cancer, Vol. 35, Iss. 3, 1999-03 ,pp. : 410-412

Elsevier

Access to resources Recommend Favorite

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

By Svancarova L.   Blay J.Y.   Judson I.R.   van Hoesel Q.G.C.M.   van Oosterom A.T.   le Cesne A.   Keizer H.J.   Hermans C.   van Glabbeke M.   Verweij J.   Hogendoorn P.C.W.   Nielsen O.S.  

European Journal of Cancer, Vol. 38, Iss. 4, 2002-03 ,pp. : 556-559

Elsevier

Access to resources Recommend Favorite

Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group - is it feasible?

By Nielsen O.S.   Judson I.   van Hoesel Q.   le Cesne A.   Keizer H.J.   Blay J.Y.   van Oosterom A.   Radford J.A.   Svancarova L.   Krzemienlecki K.   Hermans C.   van Glabbeke M.   Oosterhuis J.W.   Verweij J.  

European Journal of Cancer, Vol. 36, Iss. 1, 2000-01 ,pp. : 61-67

Elsevier

Access to resources Recommend Favorite

Imatinib mesylate (STI-571 Glivec(R), Gleevec(TM)) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target - Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study

By Verweij J.   van Oosterom A.   Blay J.-Y.   Judson I.   Rodenhuis S.   van der Graaf W.   Radford J.   Le Cesne A.   Hogendoorn P.C.W.   di Paola E.D.   Brown M.   Nielsen O.S.  

European Journal of Cancer, Vol. 39, Iss. 14, 2003-09 ,pp. : 2006-2011

Elsevier

Access to resources Recommend Favorite